Depression - A mental state of depressed mood characterized by feelings of sadness, despair and discouragement. Depression ranges from normal feelings of the blues through dysthymia to major depression.
Aripiprazole as adjunctive therapy in major depressive disorder
Depression :: Aripiprazole as adjunctive therapy in major depressive disorder
In adults with major depressive disorder, adding aripiprazole to antidepressant therapy (ADT) resulted in significant improvement in the primary endpoint, the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.These findings are from one of two completed studies evaluating adjunctive aripiprazole with ADT.
?Investigational studies are important because many patients with major depressive disorder do not achieve adequate symptom response,? said study investigator Arif Khan, M.D., Medical Director, Northwest Clinical Research Center, Bellevue, Wash., and Adjunct Professor, Psychiatry, Duke University, Durham, N.C. ?The findings from this study contribute more information about the potential use of add-on medications to antidepressant therapy in patients who inadequately respond to antidepressants alone.?
Study Design and Findings
This double-blind, randomized, placebo-controlled, multi-center, six-week study enrolled adults diagnosed with major depressive disorder who had an inadequate response to one or more ADTs. After a seven to 28-day screening phase, adults in this study underwent an eight-week prospective treatment phase with one ADT plus single-blind placebo to confirm their inadequate response to ADT. The ADTs included escitalopram, fluoxetine, paroxetine controlled release, sertraline or venlafaxine extended release, dosed per label guidelines. A total of 362 adults with inadequate response then entered the six-week randomized treatment phase during which they continued their ADT plus double-blind adjunctive placebo or adjunctive aripiprazole (2-20 mg/day).
The primary efficacy endpoint was the mean change from baseline ? the end of the prospective treatment phase ? to the end of the randomized treatment phase in a standard measure called the MADRS Total Score, which can range from 0 (no symptoms) to 60 points (most severe symptoms). A reduction in MADRS Total Score represents improvement in depressive symptoms. Some of the secondary endpoints included Sheehan Disability Scale (SDS), MADRS-measured remission and response rates and Clinical Global Impression-Severity of Illness (CGI-S) score.
For the primary endpoint, the study showed that adults taking adjunctive aripiprazole had a greater reduction in MADRS Total Score from baseline compared to placebo (-8.8 vs. -5.8 points, p-value less than 0.001).
The discontinuation rate due to an adverse event for adults taking add-on aripiprazole was 3.3 percent and 2.3 percent for placebo. The most common adverse events in the add-on aripiprazole and add-on placebo groups, respectively, (greater than or equal to 5 percent and at least twice the incidence of placebo) were akathisia (23.1 percent vs. 4.5 percent), insomnia (7.7 percent vs. 2.3 percent), restlessness (14.3 percent vs. 3.4 percent), upper respiratory tract infection (8.2 percent vs. 4 percent), and blurred vision (6.6 percent vs. 1.7 percent).
(Depression :: Aripiprazole as adjunctive therapy in major depressive disorder published at SpiritIndia on Tuesday, May 22, 2007)
Depression
Search more information on Depression, Depression booksRecently posted related articles on Depression :
- Depression :: Correcting poor vision in nursing home residents may decrease symptoms of depression
- Depression :: Depression and homoeopathy
- Resilience :: Ability to handle stress, depression linked to brain mechanism
- Depression :: CPAP therapy improves symptoms of depression in OSA patients
- Depression :: Anti-depressant drugs can double risk of gastrointestinal bleeding
- Depression :: Depression can foreshadow intellectual decline in older people
- Depression :: Sex and depression - gender can affect your mental health
- Depression :: Take part in National Depression Screening Day, US
- Depression :: Medication and psychotherapy appears most effective for treatment of depressed teens
- Heart Disease :: Depression, aging, and proteins made by a virus may all play role in heart disease
Most related articles:
- Depression :: Aripiprazole as adjunctive therapy in major depressive disorder- Stress :: Childhood stress leads to depressive and anxiety disorders - 12.7
- Depression :: New treatment strategy for the prevention of recurrent depression - 12.1
- Depression :: Internet questionnaire can accurately identify depression - 11.9
- Asthma :: Anxiety and depression worsen quality of life of asthma patients - 10.4
- Depression :: Fabre-Kramer refiles gepirone ER with the FDA for the treatment of major depressive disorder - 10.3
- Bipolar Depression :: AstraZeneca's SEROQUEL for Bipolar Depression Treatment - 10.2
- Depression :: Adding medication improves recovery for elderly with depression - 9.6
- Pregnancy :: Depression often not treated in pregnant women - 9.2
- Depression :: Rumination may trigger neuroticism and depression - 8.9
Depression - recent related articles/news stories:
- Yoga benefits back pain patients- 15% preschoolers have high levels of depression and anxiety
- Hopelessness increases stroke risk in women
- Genetic link to placebo response in depression
- Students with depression likely to drop out of college
»» Infectious Disease :: Scientists concerned about effects of global warming on infectious diseases
«« Healing :: Patient's own platelets may speed up skin wound healing
The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com